Columbia University Medical Center - CUMC

New York, New York 10032

1 studies enrolling now · 12 studies all time

What they study most

Advanced Cancer, Brain Cancer, Chronic Phase Chronic Myeloid Leukemia, Fibrosis, Focal Segmental Glomerulosclerosis, Inherited Mitochondrial Disease, Liver Diseases, Lymphoma. Non-Hodgkin, Minimal Change Disease, Multiple Myeloma, Nephrotic Syndrome, Non Small Cell Lung Cancer (NSCLC)

Studies at this site

• AMEND TS Early Feasibility Study — Recruiting now
• A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease — Completed
• An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) — Completed
• Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States — Completed
• A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen — Completed
• An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread — Completed
• Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139) — Completed
• A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) — Completed
• Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD) — Completed
• Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis — Completed
• Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors — Stopped early
• A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse — Completed